
Fibrobiologics Inc (FBLG) Stock Forecast & Price Target
Fibrobiologics Inc (FBLG) Analyst Ratings
Bulls say
FibroBiologics Inc. is showing a promising trajectory in its clinical development of fibroblast-based therapies owing to its progress in preclinical IND-enabling studies and the scalable production potential of its fibroblast spheroid candidates. The company's focus on addressing chronic diseases with unmet medical needs is supported by a robust intellectual property estate and efficient operating practices, despite rising expenses associated with development scale-up. Positive early results in wound healing and ongoing advancements in treatments for chronic-relapse psoriasis and multiple sclerosis indicate substantial upside potential, reinforcing an optimistic outlook for the company’s financial future.
Bears say
FibroBiologics Inc is facing significant financial challenges that contribute to a negative outlook on its stock. The company reported a net loss of $5.8 million for Q3 2025, and the stock has plummeted over 80% year-to-date, contrasting sharply with overall market growth reflected in the NBI, which is up over 20%. Furthermore, concerns regarding the company's ability to secure necessary capital, achieve projected commercial revenues, and effectively manage R&D expenses amid widening losses add to the uncertainties about its future potential.
This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.
Fibrobiologics Inc (FBLG) Analyst Forecast & Price Prediction
Start investing in Fibrobiologics Inc (FBLG)
Order type
Buy in
Order amount
Est. shares
0 shares